Wockhardt

A former official of drug maker Wockhardt on Thursday settled with Sebi a case pertaining to alleged non-disclosure of adverse observations made by the USFDA about the company's manufacturing facility to the exchanges in 2013. Vijay Khetan, who was the compliance officer of Wockhardt, paid Rs 27.06 lakh towards the settlement charges to the capital markets regulator for the alleged violations of insider trading rules, the Securities and Exchange Board of India (Sebi) said in an order. The order came after Khetan proposed to settle the pending proceedings through a settlement order. Sebi, through a show cause notice in September 2022, alleged that Khetan, being the compliance officer of Wockhardt at the relevant point of the time, had failed to ensure disclosure of price sensitive information immediately to stock exchanges. Therefore, he allegedly violated the code of conduct specified under the insider trading rules, as per the show cause notice. It was also alleged that Wockhardt

Drug firm Wockhardt plans to roll out two vaccines within a year from its UK-based facility as part of a tie-up with Serum Institute of India, a top company official said. Last year, a Wockhardt unit tied up with a subsidiary of Serum Institute of India to set up a vaccine manufacturing facility in Wrexham, North Wales (UK). "Serum has identified two vaccines and we plan to manufacture these products within the next 12 months after exhibit batches and regulatory approval is received," Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said in an analyst call. Elaborating on the tie-up, he noted that the company has already concluded an agreement with Serum and as a result of that Wockhardt has received 10 million pounds as a contribution for reserving the manufacturing facility for 150 million doses per year of vaccine for 15 years. "This is 150 million doses per year for about a 15-year agreement. And in addition to a contract manufacturing, there is a joint venture ..

Company left with low-margin brands in India after selling profitable ones

Ambuja Cements, Ceat, Eicher Motors, Pidilite Industries, Tata Chemicals, Torrent Power and Wockhardt are few of the prominent stocks holding on to the bullish outlook.

CLOSING BELL: Tata Steel fell over 4 per cent, while Asian Paints, Wipro, L&T, Bajaj twins, Ultratech Cement, Axis Bank, Sun Pharma, Tech M, ICICI Bank, & SBI declined in the range of 2-3.5 per cent

Stocks to watch today: L&T commissioned a new green hydrogen plant at Hazira in Gujarat; Future Enterprises defaults on payments of interest of two non-convertible debentures (NCDs) of Rs 12.6 crore.

Drug firm Wockhardt on Saturday said it has tied up with various partners to roll out products in the US market with its Illinois-based manufacturing plant all set to relieve all workers in a phased manner as part of business restructuring in the US market. The Mumbai-based company said it has engaged multiple US Food and Drug Administration (USFDA) approved manufacturing partners in the US market, after thorough due diligence and inspection of their facilities, to manufacture various products for sale in the US/ North America. "The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner and in full compliance with the applicable local laws," Wockhardt Ltd said in a regulatory filing. This new arrangement is in the best interest of the company as it will help avoid the manufacturing and quality management cost completely resulting in significant savings in operating and overhead co

State-owned insurance behemoth Life Insurance Corporation (LIC) reported a net profit of Rs 682.88 crore in the April-June quarter (Q1) of FY23, driven by its non-par business.

Consolidated revenue from operations were at Rs 595 crore during the period under review, down from Rs 860 crore last year.

Deal includes approved ANDAs for famotidine tablets, used in treatment and prevention of ulcers stomach and intestinal ulcers

Glenmark said its current portfolio consists of 175 products authorised for distribution in the US market and 48 ANDAs pending approval with the USFDA

Pharmaceuticals firm Wockhardt Ltd on Monday reported widening of consolidated net loss to Rs 311 crore in the fourth quarter ended March 31, 2022.

SII has supplied the AstraZeneca-Oxford vaccine to the UK already, and having a fill-and-finish facility in the UK would help the firm to have closer access to the UK and EU markets.

CLOSING BELL: Sectorally, only the Nifty IT index eked out gain on the NSE, rising 0.14 per cent

Pharma shares are likely to be in limelight as NPPA may allow up to 10 per cent hike on scheduled drugs in the month of April.

Earlier in January this year, Wockhardt's board had approved raising of up to Rs 1,000 crore through a rights issue to its existing shareholders

The approval is for the export of up to 8 crore doses of Sputnik Light and up to 2 crore doses of Sputnik V Component I vaccines, Wockhardt Ltd said in a regulatory filing

Sectorally, the Nifty PSU Bank index jumped a massive 5 per cent on the NSE, while the Nifty Bank and Private Bank indices added about a per cent each

Drug maker Wockhardt on Thursday reported a consolidated net profit of Rs 1.77 crore for the third quarter of 2021

Pharma shares may be in focus as India's apex health research organization ICMR has raised concerns around the safety for use of the oral antiviral drug Molnupiravir